<DOC>
	<DOCNO>NCT00565227</DOCNO>
	<brief_summary>Vorinostat ( Suberoylanilide Hydroxamic Acid ; NSC 701852 ) drug inhibits enzyme play key role regulation cell survival , growth , eventual cell death , play role cancer . As result , drug potential affect tumor 's ability survive . Vorinostat potent drug kind currently investigation clinical trial . The primary objective study define maximum safe dose vorinostat combination standard chemotherapy agent , docetaxel , patient advance relapsed lung , bladder , prostate cancer .</brief_summary>
	<brief_title>Phase I Study Vorinostat Combination With Docetaxel Patients With Advanced Relapsed Solid Malignancies .</brief_title>
	<detailed_description>Vorinostat ( also know Suberoylanilide Hydroxamic Acid ) new investigational drug approve Food Drug Administration . This drug show promising activity number cancer . We want determine treatment vorinostat combination standard type chemotherapy ( docetaxel [ Taxotereâ„¢ ] ) safe possibly well treatment docetaxel alone . We also want find patient cancer react drug , happen vorinostat human body ( body react drug break ) side effect use combination chemotherapy ( docetaxel ) . The purpose study : - Test safety research study drug , vorinostat - To determine toxicity severe side effect occur combine vorinostat docetaxel ( standard chemotherapy treatment ) - To study body take , break responds vorinostat - To obtain evidence ability vorinostat react cancer , kind . The use vorinostat combination chemotherapy docetaxel may result improved response cancer treatment . Indeed , vorinostat may add benefit docetaxel promote cancer cell death . This drug interfere ability cancer grow , although way vorinostat clearly define . Vorinostat docetaxel disrupt cancer 's ability produce daughter cancer cell therefore , administration vorinostat docetaxel hop good either drug alone .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>1 . There limit prior course chemotherapy long regimen contain docetaxel . Prior use paclitaxel ( Taxol ) taxanes permissible . 2 . Only patient nonsmall cell lung , prostate , bladder/urothelial cancer progress chemotherapy hormone therapy . 1 . Patients chemotherapy radiotherapy within 3 week . 2 . Patients may receive investigational agent prior treatment histone deacetylase ( HDAC ) inhibitor ( i.e . Valproic acid , PXD001 , Depsipeptide , MS275 LAQ824 ) 3 . Significant cardiovascular disease include congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>